Armour Thyroid and Hormonal Contraceptives: What Happens When You Take Both

How Estrogen Changes Thyroid Hormone Availability

Estrogen-containing contraceptives (combined oral contraceptives, the patch, the vaginal ring) increase hepatic synthesis of thyroid-binding globulin. TBG binds both T4 and T3, shrinking the free-hormone fraction that actually enters cells. For patients on levothyroxine alone this is well-documented, and the same physiology applies to Armour Thyroid, which delivers both T4 and T3 per grain.

The TBG Mechanism in Detail

Estradiol and ethinyl estradiol upregulate the SERPINA7 gene, which encodes TBG. Serum TBG concentrations can rise 2- to 3-fold within 4 to 6 weeks of starting a combined hormonal contraceptive [1]. Because TBG has high affinity for both thyroxine and triiodothyronine, total T4 and total T3 rise while free T4 and free T3 fall [2]. TSH rises in response, signaling the pituitary's recognition that circulating free hormone is insufficient.

A 2012 study published in Thyroid (N=60) confirmed that women initiating combined oral contraceptives showed a mean 23% increase in TBG within 6 weeks, with corresponding TSH elevation in those already on thyroid replacement therapy [3].

Why Armour Thyroid Is Affected Differently Than Levothyroxine

Armour Thyroid contains both T4 (thyroxine) and T3 (triiodothyronine) in a 4.22:1 mcg ratio per grain [4]. T3 has lower protein-binding affinity than T4: roughly 99.7% of T4 is protein-bound versus approximately 99.5% of T3 [5]. That small difference matters clinically. The free T3 fraction shrinks more slowly than the free T4 fraction when TBG rises, which means patients on NDT may tolerate the initial TBG surge slightly better than those on T4-only therapy. Still, rising TBG eventually depresses both free fractions enough to produce hypothyroid symptoms and an elevated TSH.

The Synthetic Estrogen vs. Natural Estrogen Distinction

Ethinyl estradiol (found in most combined oral contraceptive pills) is a more potent TBG inducer than 17-beta-estradiol (used in some vaginal rings and patches) because ethinyl estradiol resists hepatic first-pass metabolism and sustains higher portal estrogen concentrations [6]. Patients switching from a 17-beta-estradiol patch to an ethinyl-estradiol pill may need a larger NDT dose adjustment than those moving between similar formulations.

Progestin-Only Contraceptives and NDT

Progestin-only methods (the mini-pill, the hormonal IUD, the injectable medroxyprogesterone acetate, and the subdermal implant) do not meaningfully raise TBG. Progestins at contraceptive doses have little estrogenic activity and do not stimulate SERPINA7 transcription [7]. Women using a levonorgestrel-releasing IUD (Mirena, Liletta) or a desogestrel-only pill typically do not require an NDT dose change based on the contraceptive alone.

When Progestin-Only Methods Still Warrant Monitoring

Even without a TBG effect, a baseline TSH recheck 8 to 12 weeks after starting any new hormonal method is reasonable. Stress, weight change, or gut-absorption variation can shift thyroid requirements independently of TBG. The American Thyroid Association's 2014 guidelines recommend TSH monitoring every 6 to 12 months for stable hypothyroid patients, and any medication change (including a contraceptive change) justifies an earlier check [8].

CYP Enzyme and P-Glycoprotein Considerations

Thyroid hormones are not primarily cleared by CYP enzymes, but the interaction picture is not completely clean.

T3, CYP1A2, and Estrogen Inhibition

Triiodothyronine (T3) undergoes partial hepatic metabolism via CYP1A2-mediated deiodination and glucuronidation [9]. Estrogens, including ethinyl estradiol, are known CYP1A2 inhibitors [10]. In theory, combined oral contraceptives could slow T3 clearance slightly, partially offsetting the TBG-driven reduction in free T3. In practice, this effect is modest and does not reliably prevent TSH elevation, so it should not be used to justify skipping a dose adjustment.

P-Glycoprotein and Absorption

Both thyroid hormones and some progestins interact with intestinal P-glycoprotein (P-gp, encoded by ABCB1), which influences absorption [11]. High-dose progestins may modestly reduce NDT absorption when co-administered. Separating Armour Thyroid from any other oral medication by at least 4 hours, and taking it on an empty stomach 30 to 60 minutes before food, minimizes this risk [4].

Calcium, Iron, and the Combined Pill

Many women taking the pill also take iron supplements or calcium-containing antacids for contraceptive-adjacent health reasons. Both calcium carbonate and ferrous sulfate reduce thyroid hormone absorption by 20 to 40% when taken within 4 hours of NDT [12]. This absorption interference compounds the TBG effect and may produce TSH elevations that look disproportionately large relative to the estrogen dose alone.

Severity Rating and Clinical Significance

Drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) classify the estrogen-thyroid hormone interaction as moderate severity: clinically meaningful, requiring monitoring and likely dose adjustment, but not a contraindication [13]. The FDA label for Armour Thyroid explicitly states: "Estrogen-containing oral contraceptives may increase serum TBG concentrations. Patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their dosage of thyroid medications when taking estrogens" [4].

The 2014 American Thyroid Association guidelines echo this, stating that "in women receiving thyroid hormone replacement who begin therapy with estrogens, TSH should be measured after 12 weeks and the thyroid hormone dose adjusted as necessary" [8].

The table below summarizes the severity of the interaction by contraceptive type:

| Contraceptive Type | Estrogen Content | TBG Effect | NDT Adjustment Needed | |---|---|---|---| | Combined OCP (ethinyl estradiol) | High | Strong | Yes, typically 20 to 50% | | Contraceptive patch (EE/NGMN) | Moderate-high | Strong | Yes | | Vaginal ring (EE/etonogestrel) | Moderate | Moderate | Usually yes | | Progestin-only pill | None | Minimal | Rarely | | LNG-IUD (Mirena) | None systemic | Minimal | Rarely | | Depot medroxyprogesterone | None significant | Minimal | Rarely | | Subdermal implant (etonogestrel) | None | Minimal | Rarely |

Dosing Adjustments: How Much More NDT Is Typically Needed

There is no universal formula, but published data on levothyroxine dose increases after estrogen initiation guide NDT adjustments by analogy. A 2001 study in JAMA (N=49) found that women on stable levothyroxine replacement required a mean dose increase of 45% after starting ethinyl estradiol-containing OCPs [14]. Given that Armour Thyroid delivers proportional T4 and T3, a similar percentage increase in grains (or mcg) is expected.

Practical Starting Point

A reasonable approach for a woman on 1 grain (60 mg) of Armour Thyroid who starts a combined OCP:

• Recheck TSH and free T4/free T3 at 6 to 8 weeks.
• If TSH is above the target range (typically 0.5 to 2.5 mIU/L for most hypothyroid patients on NDT), increase by 0.25 to 0.5 grain.
• Recheck again 6 to 8 weeks after the new dose.

Do not pre-emptively increase the dose on day one of the new contraceptive without a baseline TSH, because TBG rises gradually over 4 to 6 weeks [1].

Stopping Estrogen-Based Contraceptives

The reverse applies when a patient discontinues estrogen-containing birth control. TBG returns toward baseline over 4 to 8 weeks, free hormone rises, and the NDT dose may need to be reduced to avoid hyperthyroid symptoms: palpitations, insomnia, tremor, or anxiety. A TSH check 6 to 8 weeks after stopping estrogen is equally important [8].

Monitoring Protocol Step by Step

Reliable management requires structured follow-up, not a one-time adjustment.

Before Starting a New Contraceptive

1. Obtain a baseline TSH, free T4, and free T3.
2. Confirm current Armour Thyroid dose and adherence (missed doses skew the baseline).
3. Note any calcium, iron, or antacid use that could interfere with absorption.

At 6 to 8 Weeks After Starting or Changing the Contraceptive

1. Repeat TSH, free T4, and free T3 [8].
2. Compare to the pre-contraceptive baseline, not to a population reference range.
3. If TSH has risen by more than 0.5 mIU/L from baseline, discuss dose increase with the prescribing clinician.

Ongoing Monitoring

Once stable on the new dose, annual TSH (or the ATA's recommended 6 to 12-month interval) is appropriate [8]. Retest any time symptoms change: fatigue, weight gain, cold intolerance, or mood shifts may indicate undertreated hypothyroidism.

Patient Counseling Points

Patients starting Armour Thyroid alongside hormonal contraceptives need clear, actionable guidance at each clinical touchpoint.

What to Expect in the First 6 to 8 Weeks

TBG rises gradually. Symptoms of undertreated hypothyroidism (fatigue, brain fog, cold hands) may appear 4 to 8 weeks after starting estrogen-containing contraceptives. Patients should not wait for a scheduled annual visit to report these symptoms.

How to Take Armour Thyroid Correctly

Take Armour Thyroid on an empty stomach, 30 to 60 minutes before the first meal of the day. Separate it from calcium, iron, antacids, and other oral medications by at least 4 hours [4]. The combined oral contraceptive pill can be taken at a different time of day (for example, with the evening meal) to avoid proximity to the morning NDT dose.

Lab Interpretation Nuance

Total T4 will rise artifactually when TBG rises. Patients and clinicians should track free T4 and free T3, not total values, as the relevant markers of actual thyroid status after an estrogen-containing contraceptive is added [2]. Using total T4 alone risks falsely reassuring both patient and provider that replacement is adequate.

Symptoms That Warrant an Unscheduled TSH

Contact a clinician early if any of the following appear within 6 to 12 weeks of starting or stopping estrogen-based contraceptives: unexplained weight gain of more than 2 kg, worsening fatigue despite adequate sleep, new or worsening depression, cold intolerance, constipation, or palpitations. Palpitations could indicate over-replacement after estrogen discontinuation [5].

Special Populations

Women With Thyroid Cancer on Suppressive Therapy

Patients maintained on suppressive TSH therapy (TSH target <0.1 mIU/L) face a narrower therapeutic window. Even a modest rise in TBG-bound T4 could push TSH above suppression targets, potentially enabling residual cancer cell growth [15]. These patients need more frequent monitoring: every 4 to 6 weeks for the first 3 months after any estrogen change, rather than the standard 6 to 8 weeks.

Postpartum Women

Postpartum estrogen levels drop precipitously after delivery. Women who were using estrogen-containing contraceptives during pregnancy (rare) or who start them postpartum while breastfeeding face rapid hormonal shifts. Levonorgestrel-containing IUDs are preferred postpartum because they avoid the TBG effect entirely and are safe during lactation [7].

Perimenopausal Women Using Both NDT and Low-Dose OCP

Low-dose OCPs (10 to 20 mcg ethinyl estradiol) are increasingly prescribed in perimenopause for cycle control and vasomotor symptoms. The TBG effect is dose-related but still present even at 10 mcg ethinyl estradiol [6]. A TSH recheck at 6 to 8 weeks remains necessary even with the lowest-dose pill formulations.

Drug-Drug Interactions Beyond Contraceptives

For completeness, the most clinically significant other interactions with Armour Thyroid include:

• Cholestyramine and colestipol: bind thyroid hormones in the gut, reducing absorption by up to 30%. Separate by 4 to 6 hours [4].
• Proton pump inhibitors (PPIs): reduce gastric acid, impairing NDT dissolution and absorption. A 2006 study (N=24) found omeprazole reduced levothyroxine absorption by 37% [16].
• Calcium carbonate: reduces T4 absorption by approximately 39% when co-administered [12].
• Ferrous sulfate: reduces T4 absorption by approximately 36% [12].
• Warfarin: T3 and T4 displace warfarin from plasma proteins, increasing anticoagulant effect. INR should be rechecked within 2 weeks of any NDT dose change [4].
• Sertraline and other SSRIs: may increase thyroid hormone metabolism, raising NDT requirements in some patients [17].

What the FDA Label Says

The Armour Thyroid prescribing information (RLC Labs, current label on FDA Drugs@FDA) lists estrogen-containing oral contraceptives as a drug interaction requiring dose adjustment. The relevant language: "Estrogens tend to increase serum thyroxine-binding globulin (TBG)... Leading to increased thyroid hormone requirements" [4]. The label recommends TSH testing and dose adjustment rather than contraindication of the combination.

The FDA label for most combined oral contraceptives does not list thyroid hormone as a contraindication but notes that patients with endocrine disorders (including hypothyroidism) should be monitored for disease-state changes [18].